
    
      The purpose of this post-approval study is to provide supplementary information relating to
      the use of Xyntha (Moroctocog-alfa (AF-CC), Recombinant FVIII) in Chinese subjects with
      hemophilia A, especially on the safety and efficacy in different populations of Chinese
      hemophilia A patients, in particular in pediatric patients <6 years of age, pediatric
      patients ≥6 to ≤12 years of age, Previously Untreated Patients (PUPs) , subjects receiving
      prophylaxis treatment after enrollment in the study, and severe patients (FVIII:C <1%).
    
  